Oramed Initiates Patient Recruitment for a New Clinical Trial in Israel of its Oral Insulin Drug ORMD-0801 in the Treatment of

Oramed Initiates Patient Recruitment for a New Clinical Trial in Israel of its
       Oral Insulin Drug ORMD-0801 in the Treatment of Type 1 Diabetes

ORMD-0801 US FDA trial for the treatment of type 2 diabetes is already in
progress

PR Newswire

JERUSALEM, August 21, 2013

JERUSALEM, August 21, 2013 /PRNewswire/ --

Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a
developer of oral drug delivery systems, announced today that it has initiated
patient recruitment for a new clinical trial of its orally ingestible insulin
capsule, ORMD-0801 for patients with type 1 diabetes mellitus (T1DM) in
Israel.

"We are very excited to continue our development of ORMD-0801 for this
high-need indication. We have been encouraged by our successful T1DM trials to
date and we look forward to the commencement of this study," commented Oramed
CEO Nadav Kidron.

Prior clinical studies have shown that ORMD-0801 administered to T1DM patients
just prior to a meal effectively kept their blood sugar levels stable. The
results of one such trial were published earlier this year in the
international, peer-reviewed journal PLOS ONE. The research article titled,
"Glucose-Reducing Effect of the ORMD-0801 Oral Insulin Preparation in Patients
with Uncontrolled Type 1 Diabetes: A Pilot Study," can be accessed on the
publication's site:
http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0059524

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery
solutions for drugs and vaccines currently delivered via injection.
Established in 2006, Oramed's technology is based on over 30 years of research
by top research scientists at Jerusalem's Hadassah Medical Center. Oramed is
seeking to revolutionize the treatment of diabetes through its proprietary
flagship product, an orally ingestible insulin capsule (ORMD-0801) currently
initiating Phase 2 clinical trials on patients with type 2 diabetes (T2DM)
under an Investigational New Drug application with the U.S. Food and Drug
Administration, and with its oral exenatide capsule (ORMD-0901; a GLP-1
analog), with trials on healthy volunteers (Phase 1b) and T2DM patients (Phase
2a) underway. Oramed is also moving forward with clinical trials of ORMD-0801
for the treatment of type 1 Diabetes. The Company's corporate and R&D
headquarters are based in Jerusalem.

For more information, the content of which is not part of this press release,
please visit http://www.oramed.com.

Forward-looking statements: This press release contains forward-looking
statements. For example, we are using forward-looking statements when we
discuss our clinical trials or revolutionizing the treatment of diabetes with
our products. These forward-looking statements and their implications are
based on the current expectations of the management of Oramed only, and are
subject to a number of factors and uncertainties that could cause actual
results to differ materially from those described in the forward-looking
statements, including the risks and uncertainties related to the progress,
timing, cost, and results of clinical trials and product development programs;
difficulties or delays in obtaining regulatory approval or patent protection
for our product candidates; competition from other pharmaceutical or
biotechnology companies; and our ability to obtain additional funding required
to conduct our research, development and commercialization activities. In
addition, the following factors, among others, could cause actual results to
differ materially from those described in the forward-looking statements:
changes in technology and market requirements; delays or obstacles in
launching our clinical trials; changes in legislation; inability to timely
develop and introduce new technologies, products and applications; lack of
validation of our technology as we progress further and lack of acceptance of
our methods by the scientific community; inability to retain or attract key
employees whose knowledge is essential to the development of our products;
unforeseen scientific difficulties that may develop with our process; greater
cost of final product than anticipated; loss of market share and pressure on
pricing resulting from competition; laboratory results that do not translate
to equally good results in real settings; our patents may not be sufficient;
and final that products may harm recipients, all of which could cause the
actual results or performance of Oramed to differ materially from those
contemplated in such forward-looking statements. Except as otherwise required
by law, Oramed undertakes no obligation to publicly release any revisions to
these forward-looking statements to reflect events or circumstances after the
date hereof or to reflect the occurrence of unanticipated events. For a more
detailed description of the risks and uncertainties affecting Oramed,
reference is made to Oramed's reports filed from time to time with the
Securities and Exchange Commission.

Company Contact:
Oramed Pharmaceuticals
Aviva Sherman
Office: +972-2-566-0001
Mobile: +972-54-792-4438
Email: aviva@oramed.com

SOURCE Oramed Pharmaceuticals Inc.
 
Press spacebar to pause and continue. Press esc to stop.